Condition

Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) (3)

Chronic Myelogenous Leukemia (2)

ALL, Adult (1)

Hypereosinophilic Syndrome (1)

Philadelphia-Positive ALL (1)

Systemic Mastocytosis (1)

Overall Status

Completed (2)

Recruiting (1)

Sign in for free

Phase

phase 1/phase 2 (2)

phase 3 (1)

Sponsor

Novartis Pharmaceuticals (2)

Gruppo Italiano Malattie EMatologiche dell'Adulto (1)

Collaborator

Intervention

nilotinib (2)

chemotherapy + imatinib (1)

ponatinib + blinatumomab (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Industry (2)

Other (1)

Study Type

Interventional (3)

acute lymphoblastic leukemia (philadelphia chromosome positive)

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL Trial in Italy (Ponatinib

Recruiting

Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
+2 more

Ponatinib + Blinatumomab
Chemotherapy + Imatinib

Ascoli Piceno, Italy
+14 more

Jan 3, 2022

Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome Trial

Completed

Chronic Myelogenous Leukemia
+3 more

Nilotinib

Duarte, California
+100 more

Jun 8, 2021

Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) Trial in Tokyo (Nilotinib)

Completed

Chronic Myelogenous Leukemia
Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

Nilotinib

Tokyo, Japan

Novartis Investigative Site

Dec 6, 2020